课题基金 / 基金详情

RITUXIMAB IN RENAL ALLOGRAFT RECIPIENTS WITH EARLY ANTI-HLA ALLOANTIBODIES

RITUXIMAB IN RENAL ALLOGRAFT RECIPIENTS WITH EARLY ANTI-HLA ALLOANTIBODIES
利妥昔单抗在具有早期抗 HLA 同种抗体的同种异体肾移植受者中的应用
批准号:
7606964
负责人:
MARTHA PAVLAKIS
金额:
$0.53万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2008-03-31

项目摘要

项目成果

MARTHA PAVLAKIS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, single-blinded, randomized, placebo-controlled trial. Centers will screen 1200-1400 subjects and will randomize a total of 134 subjects over 3 years. The primary endpoint of this study is the effectiveness of B-cell depletion by anti-CD20 mAb therapy in reducing progression of chronic renal allograft dysfunction by chronic humoral rejection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: RITUXIMAB IN RENAL ALLOGRAFT RECIPIENTS WITH EARLY ANTI-HLA ALLO
ISLET TRANSPLANTATION IN TYPE I DIABETIC REICIPIENTS OF RENAL ALLOGRAFT USING TH
ISLET CELL TRANSPLANTS FOR DIABETES IN KIDNEY TRANSPLANT PATIENTS
Islet Cell Transplants for Diabetes in Kidney Transplant Patients
海外基金